PERK

A novel therapeutic target for neurodegenerative diseases?

Tao Ma, Eric Klann

Research output: Contribution to journalArticle

Abstract

Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative diseases. The promise and caveats of applying this strategy for disease therapy also are discussed.

Original languageEnglish (US)
Article number30
JournalAlzheimer's Research and Therapy
Volume6
Issue number3
DOIs
StatePublished - May 29 2014

Fingerprint

Neurodegenerative Diseases
Prion Diseases
Endoplasmic Reticulum Stress
Therapeutics
Endoplasmic Reticulum
Protein Kinases
Parkinson Disease
Alzheimer Disease
Phosphotransferases
RNA
Phenotype

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cognitive Neuroscience

Cite this

PERK : A novel therapeutic target for neurodegenerative diseases? / Ma, Tao; Klann, Eric.

In: Alzheimer's Research and Therapy, Vol. 6, No. 3, 30, 29.05.2014.

Research output: Contribution to journalArticle

@article{b5caf075740d4c8a813e22f93ed90cfc,
title = "PERK: A novel therapeutic target for neurodegenerative diseases?",
abstract = "Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative diseases. The promise and caveats of applying this strategy for disease therapy also are discussed.",
author = "Tao Ma and Eric Klann",
year = "2014",
month = "5",
day = "29",
doi = "10.1186/alzrt260",
language = "English (US)",
volume = "6",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - PERK

T2 - A novel therapeutic target for neurodegenerative diseases?

AU - Ma, Tao

AU - Klann, Eric

PY - 2014/5/29

Y1 - 2014/5/29

N2 - Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative diseases. The promise and caveats of applying this strategy for disease therapy also are discussed.

AB - Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative diseases. The promise and caveats of applying this strategy for disease therapy also are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84901803359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901803359&partnerID=8YFLogxK

U2 - 10.1186/alzrt260

DO - 10.1186/alzrt260

M3 - Article

VL - 6

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 3

M1 - 30

ER -